Halkova Tereza, Cuperkova Romana, Minarik Marek, Benesova Lucie
Center for Applied Genomics of Solid Tumors (CEGES), Genomac Research Institute, Drnovska 1112/60, 161 00 Prague 6, Czech Republic.
Center for Applied Genomics of Solid Tumors (CEGES), Genomac Research Institute, Drnovska 1112/60, 161 00 Prague 6, Czech Republic ; Internal Clinic, 1st Faculty of Medicine, Charles University and Central Military Hospital, Military Faculty Hospital, U Vojenske Nemocnice 1200, 169 02 Prague 6, Czech Republic.
Gastroenterol Res Pract. 2015;2015:892903. doi: 10.1155/2015/892903. Epub 2015 Apr 19.
Pancreatic cancer is one of the most fatal malignancies with increasing incidence and high mortality. Possibilities for early diagnosis are limited and there is currently no efficient therapy. Molecular markers that have been introduced into diagnosis and treatment of other solid tumors remain unreciprocated in this disease. Recent discoveries have shown that certain microRNAs (miRNAs) take part in fundamental molecular processes associated with pancreatic cancer initiation and progression including cell cycle, DNA repair, apoptosis, invasivity, and metastasis. The mechanism involves both positive and negative regulation of expression of protooncogenes and tumor suppressor genes. Various miRNAs are expressed at different levels among normal pancreatic tissue, chronic pancreatitis, and pancreatic cancer and may therefore serve as a tool to differentiate chronic pancreatitis from early stages of cancer. Other miRNAs can indicate the probable course of the disease or determine the survival prognosis. In addition, there is a growing interest directed at the understanding of miRNA-induced molecular mechanisms. The possibility of intervention in the molecular mechanisms of miRNAs regulation could begin a new generation of pancreatic cancer therapies. This review summarizes the recent reports describing functions of miRNAs in cellular processes underlying pancreatic cancerogenesis and their utility in diagnosis, survival prognosis, and therapy.
胰腺癌是最致命的恶性肿瘤之一,其发病率不断上升且死亡率很高。早期诊断的可能性有限,目前尚无有效的治疗方法。已应用于其他实体瘤诊断和治疗的分子标志物在这种疾病中尚未得到应用。最近的研究发现,某些微小RNA(miRNA)参与了与胰腺癌发生和发展相关的基本分子过程,包括细胞周期、DNA修复、细胞凋亡、侵袭和转移。其机制涉及原癌基因和抑癌基因表达的正负调控。在正常胰腺组织、慢性胰腺炎和胰腺癌中,各种miRNA的表达水平不同,因此可作为区分慢性胰腺炎和癌症早期阶段的工具。其他miRNA可以指示疾病的可能进程或确定生存预后。此外,人们对理解miRNA诱导的分子机制的兴趣日益浓厚。干预miRNA调控分子机制的可能性可能会开启新一代胰腺癌治疗方法。本综述总结了最近关于miRNA在胰腺癌发生的细胞过程中的功能及其在诊断、生存预后和治疗中的应用的报道。